Canadian Pfizer partner sues to head off patent lawsuit over COVID-19 vaccine


The biotech firm that makes mRNA-delivery expertise for Pfizer's COVID-19 vaccine sued Arbutus Biopharma in Manhattan federal court docket on Friday, searching for to go off claims that the vaccine infringes Arbutus' patents.


Canada-based Acuitas Therapeutics stated Arbutus and associate Genevant Sciences have threatened to sue for probably billions of dollars in "unjustified royalties" over the vaccine Pfizer developed with Germany's BioNTech.


Acuitas requested the court docket to search out that the Pfizer/BioNTech vaccine doesn't infringe Arbutus patents and that a number of Arbutus patents are invalid.


A consultant for Arbutus didn't instantly reply to a request for touch upon Acuitas' claims.


Acuitas chief government Thomas Madden stated in an announcement that the corporate stays assured in its expertise however in any other case declined to touch upon the lawsuit.


The lawsuit is a part of a rising net of patent disputes over COVID-19 vaccine expertise. Arbutus sued Moderna over its mRNA expertise final month, however has not but sued Pfizer or Acuitas.


Pfizer and Moderna have been hit with patent lawsuits on Thursday by Alnylam Prescription drugs, which argued its personal lipid nanoparticle mRNA-delivery expertise was "important" to each of the broadly used COVID-19 vaccines.


Pfizer stated final month that it anticipated US$32 billion in income from its vaccine this 12 months. Moderna has stated its vaccine earned the corporate $17.7 billion in income in 2021.

Post a Comment

Previous Post Next Post